• Latest Posts

Sosei Heptares hails ‘transformational’ acquisition

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

More News! 9 Nov 2022

PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way


Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia

Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases